Preclinical biotech Synthorx needs a USD 100 Million IPO
The early-stage Synthorx needs USD 100 million IPO. A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million from an IPO to progress its pipelines of synthetic cytokines, which are designed to improve the efficacy of immuno-oncology treatments without the negative side effects that sometimes come with native cytokines.
Deerfield puts up USD 80 Million to pursue protein degradation R&D
Deerfield Management is setting up USD 80 million to fund the creation of a new Center for Protein Degradation at the Dana-Farber Cancer Institute. The goals of the pro...
